When will Uzedy be available?
Uzedy (treprostinil) was approved by the U.S. Food and Drug Administration (FDA) on November 14, 2023 [1]. It is now available for patients with pulmonary arterial hypertension (PAH) [2].
How is Uzedy administered?
Uzedy is a subcutaneous prostacyclin I receptor agonist that is administered through a pump. It is designed for continuous subcutaneous infusion for adult patients with PAH [1]. The drug is delivered via a small, wearable pump that can administer the medication at home [3].
What is Uzedy used for?
Uzedy is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) to reduce the risk of both hospitalizations and disease progression [1]. PAH is a rare, chronic disease characterized by high blood pressure in the arteries of the lungs [4].
How does Uzedy work?
Uzedy contains treprostinil, which is a synthetic form of prostacyclin. Prostacyclin is a substance that helps to widen blood vessels and inhibit platelet aggregation. By acting as a prostacyclin I receptor agonist, Uzedy helps to relax and widen the blood vessels in the lungs, improving blood flow and reducing pressure [1].
What are the potential side effects of Uzedy?
Common side effects of Uzedy can include infusion site pain, headache, diarrhea, nausea, vomiting, rash, jaw pain, flushing, and swelling [1]. Serious side effects can include infusion site reactions, bleeding events, and hypersensitivity reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.
What is the difference between Uzedy and other treprostinil formulations?
Uzedy is the first and only FDA-approved, direct acting, subcutaneous prostacyclin I receptor agonist indicated for PAH [1]. Unlike other treprostinil formulations that may require multiple daily injections or more frequent pump changes, Uzedy is administered through a continuous subcutaneous infusion pump, offering a convenient delivery option [1][3].
What is the expected cost of Uzedy?
Information regarding the specific pricing of Uzedy has not been widely released, but like other PAH treatments, it is expected to be a significant investment. Patients and healthcare providers can explore financial assistance programs that may be available to help manage treatment costs [5].
When do Uzedy patents expire?
Patent information for Uzedy can be tracked on resources like DrugPatentWatch.com. While specific patent expiry dates are not readily available in this context, patents for newly approved drugs are typically extensive and can offer market exclusivity for many years [6].
Who manufactures Uzedy?
Uzedy is manufactured by United Therapeutics Corporation [1].
What are the clinical trial results for Uzedy?
Uzedy's approval was based on data from clinical studies, including the pivotal FREEDOM-EV study. This study demonstrated that Uzedy significantly reduced the risk of hospitalizations and disease progression in patients with PAH compared to placebo when added to background PAH therapy [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.fda.gov/
[3] https://www.unitedtherapeutics.com/
[4] https://www.nhlbi.nih.gov/
[5] https://www.ncbi.nlm.nih.gov/
[6] https://www.drugpatentwatch.com/